Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy

BACKGROUND: In dystrophin-deficient muscles of Duchenne Muscular Dystrophy (DMD) patients and the mdx mouse model, nitric oxide (NO) signalling is impaired. Previous studies have shown that NO-donating drugs are beneficial in dystrophic mouse models. Recently, a long-term treatment (9 months) of mdx...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Orphanet J Rare Dis
Autors principals: Miglietta, Daniela, De Palma, Clara, Sciorati, Clara, Vergani, Barbara, Pisa, Viviana, Villa, Antonello, Ongini, Ennio, Clementi, Emilio
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4546261/
https://ncbi.nlm.nih.gov/pubmed/26296873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-015-0311-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars